Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanai Health Industry Group Co (HKSE:01889) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sanai Health Industry Group Co EBITDA Margin % Related Terms
Sanai Health Industry Group Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanai Health Industry Group Co EBITDA Margin % Chart
HKSE:01889 vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sanai Health Industry Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanai Health Industry Group Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanai Health Industry Group Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sanai Health Industry Group Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanai Health Industry Group Co (HKSE:01889) has a EBITDA Margin % of -32.92% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sanai Health Industry Group Co and its competitors. According to the industry distribution chart, Sanai Health Industry Group Co ranks #822 out of 961 companies in the Drug Manufacturers industry, placing it in the top 85.5%.
Is Sanai Health Industry Group Co's EBITDA Margin % too high?
Sanai Health Industry Group Co's current EBITDA Margin % is -32.92%. Based on the distribution chart, Sanai Health Industry Group Co ranks #822 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sanai Health Industry Group Co has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanai Health Industry Group Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sanai Health Industry Group Co ranks #822 out of 961 companies for EBITDA Margin %. This places Sanai Health Industry Group Co in the lower half of its industry. The industry median EBITDA Margin % is 12.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sanai Health Industry Group Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanai Health Industry Group Co's current EBITDA Margin % is -32.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanai Health Industry Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sanai Health Industry Group Co (HKSE:01889) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.42, compared to a current price of HK$0.19 — trading 53.8% below its estimated fair value. The current EBITDA Margin % is -32.92%. Sanai Health Industry Group Co's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sanai Health Industry Group Co (HKSE:01889), the current EBITDA Margin % is -32.92% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanai Health Industry Group Co (HKSE:01889) Overvalued in 2026?
Based on GuruFocus' analysis, Sanai Health Industry Group Co stock appears to be undervalued.
The current stock price of HK$0.19 is trading 53.8% below its estimated GF Value™ of HK$0.42.
GuruFocus considers Sanai Health Industry Group Co to be Possible Value Trap.
Key valuation signals for HKSE:01889:
EBITDA Margin %: -32.92%
GF Value™: HK$0.42 vs. price of HK$0.19 (53.8% below fair value)
No single metric tells the full story. See the HKSE:01889 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanai Health Industry Group Co Business Description
Sanai Health Industry Group Co Ltd is a pharmaceutical company. The company has three reportable segments namely Pharmaceutical products include development, manufacturing, marketing, and sales of pharmaceutical products and related software and provision of consultancy services. Finance leasing includes the provision of financial leasing services; Genetic testing and molecular diagnostic services segment. It generates maximum revenue from Pharmaceutical products segments. Geographically, it derives the majority of its revenue from the PRC.
40GF Score
Get the complete analysis for HKSE:01889
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01889 has been successfully added to your 
